New drug cocktail targets Hard-to-Treat breast cancer

NCT ID NCT03820141

Ongoing Disease control Sponsor: The Methodist Hospital Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding the immunotherapy drug durvalumab to two standard targeted drugs (trastuzumab and pertuzumab) can shrink tumors more effectively in people with HER2-enriched breast cancer. The study involves 51 participants and measures how many have no or minimal cancer remaining after treatment. The goal is to find a better pre-surgery option for this aggressive cancer type.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab (an immunotherapy drug) combined with trastuzumab and pertuzumab (targeted antibody drugs)
What this could lead to: If successful, this combination could offer a more effective treatment option for HER2-enriched breast cancer, potentially increasing the chance of eliminating the tumor before surgery.
What could go wrong: This is a small, early-phase trial (51 people) without a comparison group, so results may not apply broadly. Adding immunotherapy can cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Houston Methodist Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.